[Substantiation of Expressive Markers Use to Personalize Lung Cancer Chemotherapy]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacogenomics

Context:

• Lung cancer treatment, particularly for stages II-III, shows unsatisfactory surgical outcomes and limited survival benefits from standard chemotherapy.
• Current treatment strategies rely on standard clinical parameters, leading to suboptimal chemotherapy regimen selection and drug resistance.
• Tumor cell sensitivity to chemotherapeutics is significantly influenced by monoresistance genes, which are crucial in developing lung tumor resistance.

Purpose:

• To review the mechanisms of chemotherapeutic drug transport, activation, and targets in lung cancer.
• To identify key genetic markers (monoresistance genes) that predict chemotherapeutic effectiveness.
• To explore the clinical utility of these predictive markers for personalized lung cancer chemotherapy.

Summary:

• This review examines monoresistance genes like ABCC5, RRM1, ERCC1, TOP1, TOP2a, TUBB3, and TYMS, which are characteristic of lung cancer and influence drug resistance.
• It details the mechanisms of drug action and resistance, highlighting these genes as critical predictors of treatment response.
• Clinical trials supporting the use of these genes as predictive markers for lung cancer chemotherapy are discussed.

Impact:

• Establishes the role of specific monoresistance genes in predicting chemotherapeutic efficacy in lung cancer.
• Supports the development of personalized adjuvant chemotherapy strategies based on individual patient tumor genetics.
• Aims to improve treatment outcomes and survival rates for lung cancer patients through targeted therapy selection.